Stockscreener 앱 받기
2.47
0.40%
-0.010
시장 영업 전:
2.48
0.010
+0.40%
Connect Biopharma Holdings Ltd 주식(CNTB)의 최신 뉴스
BML Capital Management LLC Sells 858,613 Shares of Connect Biopharma Holdings Limited Sponsored ADR $CNTB - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
CNTB Stock Price, Quote & Chart | CONNECT BIOPHARMA HOLDINGS L (NASDAQ:CNTB) - ChartMill
Northland Securities Weighs in on CNTB Q1 Earnings - MarketBeat
Connect Biopharma asthma, COPD trials to continue as planned By Investing.com - Investing.com India
CNTB SEC FilingsConnect Biopharma Holdings Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Connect Biopharma asthma, COPD trials to continue as planned - Investing.com
Connect Biopharma Continues Phase 2 Seabreeze STAT Trials for Rademikibart in Asthma and COPD with Topline Data Expected Mid-2026 - Minichart
Connect Biopharma: DMC clears interim analysis; Phase 2 Seabreeze STAT enrollment to continue - TradingView
Connect Biopharma (NASDAQ: CNTB) DMC backs Seabreeze STAT trials, topline data mid-2026 - Stock Titan
Interim review leaves asthma, COPD drug studies unchanged ahead of mid-2026 data - Stock Titan
Connect Bio (CNTB) Stock: Market Efficiency (At Highs) 2026-04-20Trending Picks - Cổng thông tin điện tử tỉnh Lào Cai
CNTB | Connect Biopharma Holdings Limited Insider Trading - Quiver Quantitative
Connect Biopharma Holdings (CNTB) insider-linked stake of 9.6% disclosed - Stock Titan
Q1 Earnings Estimate for CNTB Issued By HC Wainwright - MarketBeat
Is Connect Bio (CNTB) Stock Consolidating | Price at $2.69, Up 2.28%Expert Stock Picks - Cổng thông tin điện tử Tỉnh Sơn La
Director at Connect Biopharma (CNTB) takes shares instead of cash pay - Stock Titan
[Form 4] Connect Biopharma Holdings Ltd Insider Trading Activity - Stock Titan
Connect Biopharma (NASDAQ:CNTB) Director James Huang Acquires 1,160,000 Shares - MarketBeat
Entity tied to CNTB director James Huang buys 1.16M shares in open market - Stock Titan
Connect Biopharma (NASDAQ: CNTB) holder Panacea adds 1.16M shares - Stock Titan
Connect Biopharma (NASDAQ:CNTB) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
ETFs Investing in Connect Biopharma Holdings Ltd. Stocks - TradingView — Track All Markets
Connect Biopharma Holdings Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update - The Manila Times
Rademikibart drives Connect Biopharma (NASDAQ: CNTB) asthma and COPD strategy - Stock Titan
[8-K] Connect Biopharma Holdings Ltd Reports Material Event - Stock Titan
New asthma and COPD drug data arrive as Connect funds operations into 2027 - Stock Titan
Connect Biopharma (NASDAQ:CNTB) Receives "Buy" Rating from BTIG Research - MarketBeat
BTIG Reiterates Buy Rating on Connect Biopharma Hldgs (CNTB) | C - gurufocus.com
BTIG reiterates Buy on Connect Biopharma stock after Phase 1 data - Investing.com Australia
BTIG reiterates Buy on Connect Biopharma stock after Phase 1 data By Investing.com - Investing.com South Africa
Connect Biopharma Announces Positive Phase 1 Results for IV Rademikibart, Showing Rapid Lung Function Improvement in Asthma and COPD Patients - Minichart
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Green Bay Press-Gazette
Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses - MarketBeat
Connect Biopharma reports positive Phase 1 data for asthma drug By Investing.com - Investing.com Australia
Connect Biopharma raises $20.2 million in private placement By Investing.com - Investing.com South Africa
Connect Biopharma stock jumps on positive drug trial results By Investing.com - Investing.com India
Connect Biopharma Announces $20.2 Million Private Placement Financing - Bitget
Connect Biopharma raises $20.2 million in private placement - Investing.com
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD - Bitget
Connect Biopharma Raises $20.2 Million in Private Placement of 6.13 Million Shares at $3.25 - TradingView
Connect Biopharma reports positive Phase 1 data for asthma drug - Investing.com
Connect Biopharma (NASDAQ: CNTB) nets $20.2M and reports promising rademikibart results - Stock Titan
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study - GlobeNewswire
Connect Biopharma Announces Positive Topline Data from its - GlobeNewswire
0.14%
0.48%
자본화:
|
볼륨(24시간):